Search Results

Senzime AB announced that it has secured a purchasing contract with the number one ranked children’s hospital system in the United States for its TetraGraph® quantitative neuromuscular monitoring system.

Inimmune Corporation announced that it has entered a research collaboration with Boston Children’s Hospital to develop novel and innovative small molecule vaccine adjuvants.

Researchers from Children’s Hospital of Philadelphia found that young children between the ages of 5 and 12 were more likely to experience a concussion from recreation and other non-sport activities, yet those injuries were not seen by specialists until days later compared with sports-related concussions in the same age group.

In a landmark study, researchers from Children’s Hospital of Philadelphia found that two separate objective assessment tools and nonverbal measurements of IQ can help assess cognitive function in children with Aicardi Goutières Syndrome, allowing treatment teams to provide appropriate support and interventions.

Eureka Therapeutics, Inc. today announced the activation of UCSF Benioff Children’s Hospitals as the first California site to join the ARYA-2 clinical trial ( NCT04634357 ).

Inozyme Pharma, Inc. announced a data presentation and sponsored symposium at the 11th International Conference on Children’s Bone Health, which is being held June 22-25, 2024, in Salzburg, Austria.

A study published Tuesday in The New England Journal of Medicine showed that children between the ages of six and 12 who took liraglutide for just over a year experienced a significant reduction in body mass index compared to placebo.

Children’s Hospital of Philadelphia announced it has entered into a Memorandum of Understanding with Sidra Medicine, a specialty healthcare organization for women, children and young people in Qatar.

MAIA Biotechnology, Inc. announced that Dr. Rachid Drissi, Principal Investigator at the Center for Childhood Cancer Research, Nationwide Children’s Hospital, and Associate Professor at Ohio State University, will present an abstract detailing the potency of THIO, MAIA’s telomere-targeting agent, as treatment for pediatric brain cancers at the American Association for Cancer Research Annual Meeting taking place April 5–10, 2024 in San Diego, California.

Eli Lilly’s new research and development facility in Boston’s Seaport district will focus on DNA- and RNA-based therapies, as well as other priority areas such as diabetes and obesity.